- The Prospective Lynch Syndrome Database: background, design, main results and complete MySQL code.
- Møller P.
- Hered Cancer Clin Pract. 2022 Nov 21;20(1):37. doi: 10.1186/s13053-022-00243-z.
- PMID: 36411472
- PubMed abstract
- Commentary
- Free Full Text
•• Identifier: NCT03565991: Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors. (ClinicalTrials.gov . Accessed 2022 Nov 19.)
•• Commentary:
Combining PARP Inhibitor With Immunotherapy-Does the Promise of Preclinical Data Translate to Clinic?
•• Research news: Largest Genetic Risk Study in Breast Cancer Reveals Differences Between Asian and European Populations. (Inside Precision Medicine)
•• Original research:
A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes.
•• Commentary:
Editorial Comment from Dr Sekino and Dr Hinata to A case of metastatic treatment emergent small cell/neuroendocrine prostate cancer with BRCA2 mutation diagnosed by liver biopsy.
•• Commentary:
Editorial Comment from Dr Kato to A case of metastatic treatment-emergent small cell/neuroendocrine prostate cancer with BRCA2 mutation by liver biopsy.